A Stanford University team led by Crystal Mackall, co-founder of Lyell Immunopharma Inc. and Obsidian Therapeutics Inc., described in Science two ways to prevent or reverse CAR T cell exhaustion. The first is based on a...

DISEASE CATEGORY: Neurology INDICATION: Alzheimer’s disease Blocking RECK, a membrane-tethered inhibitor of APP-cleaving enzyme ADAM10, could treat Alzheimer’s disease. Levels of membrane-tethered...

Although amyloid-lowering agents still represent the lion’s share of late-stage candidates for Alzheimer’s disease, they account for less than 20% of compounds across all clinical stages. Tau inhibition, modulation of neurotransmitter signaling, and quelling of...

Arctic Vision (Shanghai) Biotechnology Co. Ltd. raised $100 million in a series B round led by Loyal Valley Capital. The funds will go in part to support the company’s trio of late-stage ophthalmology programs and establish...

AnaptysBio’s Phase II miss for palmoplantar pustulosis (PPP) may indicate that overactive IL-36 signaling is not the dominant driver of the disease. The news could be a warning for Boehringer Ingelheim GmbH, which has spesolimab (BI...

Immunovant Inc. (NASDAQ:IMVT) lost 42% to $25.08 on Tuesday after announcing it was pausing trials of anti-FCRN mAb IMVT-1401 (batoclimab) due to elevated total cholesterol and LDL signals in the Phase IIb ASCEND GO-2 thyroid...

Propelled by new insights into disease biology, the clinical pipeline for ALS has grown to at least 43 programs attacking the disease from a dozen different directions. With six of those programs in Phase...

With little fuss or fanfare, the COVID R&D Alliance was created early in the pandemic by the biopharma industry’s biggest players to solve one of the world’s most devastating problems in a century....

Cytokinetics regains European rights from Servier to heart failure programCytokinetics Inc. (NASDAQ:CYTK) regained European rights to heart failure treatment omecamtiv mecarbil from Servier. The deal termination comes a month after Amgen Inc. (NASDAQ:AMGN) returned its...

The COVID R&D Alliance is looking beyond the imminent rollout of vaccines, anticipating an ongoing need for effective therapies in hospitalized COVID-19 patients. Last week, it launched the COMMUNITY...